[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020007945A - Proteinas f del rsv estabilizadas y usos de las mismas. - Google Patents

Proteinas f del rsv estabilizadas y usos de las mismas.

Info

Publication number
MX2020007945A
MX2020007945A MX2020007945A MX2020007945A MX2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A
Authority
MX
Mexico
Prior art keywords
proteins
rsv
stabilized rsv
stabilized
immunogenic compositions
Prior art date
Application number
MX2020007945A
Other languages
English (en)
Inventor
Andrew Bett
Lan Zhang
Arthur Fridman
Eberhard Durr
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020007945A publication Critical patent/MX2020007945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación se refiere a proteínas F del RSV y composiciones inmunógenas que contienen las mismas, así como métodos de uso de las composiciones inmunógenas y composiciones que comprenden las proteínas F del RSV.
MX2020007945A 2018-01-29 2019-01-24 Proteinas f del rsv estabilizadas y usos de las mismas. MX2020007945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623184P 2018-01-29 2018-01-29
PCT/US2019/014873 WO2019147749A2 (en) 2018-01-29 2019-01-24 Stabilized rsv f proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020007945A true MX2020007945A (es) 2020-09-24

Family

ID=67396243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007945A MX2020007945A (es) 2018-01-29 2019-01-24 Proteinas f del rsv estabilizadas y usos de las mismas.

Country Status (11)

Country Link
US (2) US11566051B2 (es)
EP (1) EP3746462A4 (es)
JP (1) JP7541482B2 (es)
KR (1) KR20200115567A (es)
CN (1) CN111655715A (es)
AU (1) AU2019212237A1 (es)
BR (1) BR112020015308A8 (es)
CA (1) CA3088546A1 (es)
MA (1) MA51230A (es)
MX (1) MX2020007945A (es)
WO (1) WO2019147749A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298084A (en) * 2020-05-29 2023-01-01 CureVac SE Nucleic acid-based combination vaccines
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4288087A1 (en) * 2021-02-03 2023-12-13 The Board of Trustees of the University of Illinois Vaccine and methods for preventing filariasis and dirofilariasis
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN118440937A (zh) * 2024-04-09 2024-08-06 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
EP1587816B1 (en) 2002-12-23 2010-06-16 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
EP1664316B1 (en) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
AU2006336384B2 (en) 2005-02-14 2010-12-16 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
PL2350043T3 (pl) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
JP6032724B2 (ja) 2009-03-12 2016-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
EP2444954A1 (en) 2009-06-17 2012-04-25 Sharp Kabushiki Kaisha Display driving circuit, display device and display driving method
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
CN102905763B (zh) 2009-12-23 2015-06-17 诺华股份有限公司 脂质、脂质组合物和使用它们的方法
AU2011305617A1 (en) 2010-09-20 2013-02-21 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2013078102A1 (en) 2011-11-23 2013-05-30 Merck Sharp & Dohme Corp. Method for preparation of aluminum hydroxyphosphate adjuvant
ES2981623T3 (es) 2013-03-13 2024-10-10 The United States Of America As Represented Bythe Sec Dep Of Health And Humanservices Proteínas F de RSV de prefusión y su uso
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
BR112018008078A2 (pt) * 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus influenza de amplo espectro
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
BR112018010805A2 (pt) * 2015-12-23 2018-11-27 Pfizer Inc. mutantes de proteína f de rsv
EP3436064A1 (en) 2016-03-29 2019-02-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use

Also Published As

Publication number Publication date
JP2021511356A (ja) 2021-05-06
WO2019147749A3 (en) 2019-09-19
US11566051B2 (en) 2023-01-31
MA51230A (fr) 2021-05-05
BR112020015308A8 (pt) 2023-02-07
US20230141153A1 (en) 2023-05-11
EP3746462A2 (en) 2020-12-09
RU2020128445A3 (es) 2022-02-28
WO2019147749A2 (en) 2019-08-01
JP7541482B2 (ja) 2024-08-28
EP3746462A4 (en) 2022-01-05
CN111655715A (zh) 2020-09-11
CA3088546A1 (en) 2019-08-01
AU2019212237A1 (en) 2020-07-30
BR112020015308A2 (pt) 2020-12-08
KR20200115567A (ko) 2020-10-07
US20210300971A1 (en) 2021-09-30
RU2020128445A (ru) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
PH12019501557A1 (en) Bacillus isolates and uses thereof
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2019015744A (es) Composiciones farmaceuticas.
MY193249A (en) Anti-human cd19 antibodies with high affinity
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2020008125A (es) Composiciones que comprenden berberina.
PH12021551100A1 (en) Dried biological compositions and methods thereof
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
MY191081A (en) Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
MX2020009312A (es) Derivados de polieter, usos, y metodos para hacer los mismos.
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
AU2016250265A8 (en) (S)-2'-vinyl-abscisic acid derivatives